2020 / 05

DOI: 10.24075/brsmu.2020.068

ORIGINAL RESEARCH

New anti-mesothelin single-domain antibodies and cell models for developing targeted breast cancer therapy

Kravchenko YuE, Chumakov SP, Frolova EI
About authors

Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Moscow, Russia

Correspondence should be addressed: Stepan P. Chumakov
Miklouho-Maclaya, 16/10, Moscow, 117997; moc.liamg@lukhtah

About paper

Funding: the study was supported by the Russian Ministry of Education and Science (Project ID RFMEFI60418X0205).

Compliance with ethical standards: the study was conducted in compliance with the guidelines of the Association for Assessment and Accreditation of Laboratory Animal Care International and the Directive 86/609/EEC dated November 24, 1986.

Author contribution: Kravchenko JE — cell culture, real-time PCR and ELISA; Chumakov SP — preparation of immune libraries, protein purification, flow cytometry, manuscript preparation; Frolova EI — study design, immunization and blood collection, primary cultures, manuscript preparation.

Received: 2020-09-28 Accepted: 2020-10-20 Published online: 2020-10-31
|
  1. Pastan I, Hassan R. Discovery of mesothelin and exploiting it as a target for immunotherapy. Cancer Res. 2014; 74 (11): 2907– 12. DOI: 10.1158/0008-5472.CAN-14-0337. PubMed PMID: 24824231.
  2. Einama T, Homma S, Kamachi H, Kawamata F, Takahashi K, Takahashi N, et al. Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer. Br J Cancer. 2012; 107 (1): 137–42. DOI: 10.1038/bjc.2012.235. PubMed PMID: 22644300.
  3. Kelly RJ, Sharon E, Pastan I, Hassan R. Mesothelin-targeted agents in clinical trials and in preclinical development. Mol Cancer Ther. 2012; 11 (3): 517–25. DOI: 10.1158/1535-7163.MCT-11- 0454. PubMed PMID: 22351743.
  4. Rump A, Morikawa Y, Tanaka M, Minami S, Umesaki N, Takeuchi M, et al. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem. 2004; 279 (10): 9190–8. DOI: 10.1074/jbc.M312372200. PubMed PMID: 14676194.
  5. Bharadwaj U, Marin-Muller C, Li M, Chen C, Yao Q. Mesothelin confers pancreatic cancer cell resistance to TNF-alpha-induced apoptosis through Akt/PI3K/NF-kappaB activation and IL-6/Mcl-1 overexpression. Mol Cancer. 2011; 10: 106. DOI: 10.1186/1476- 4598-10-106. PubMed PMID: 21880146.
  6. Li M, Bharadwaj U, Zhang R, Zhang S, Mu H, Fisher WE, et al. Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer. Mol Cancer Ther. 2008; 7 (2): 286–96. DOI: 10.1158/1535-7163.MCT-07-0483. PubMed PMID: 18281514.
  7. Cheng WF, Huang CY, Chang MC, Hu YH, Chiang YC, Chen YL, et al. High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma. Br J Cancer. 2009; 100 (7): 1144–53. DOI: 10.1038/sj.bjc.6604964. PubMed PMID: 19293794.
  8. Wang M, Li A, Sun G, Mbuagbaw L, Reid S, Lovrics PJ, et al. Association between mesothelin expression and survival outcomes in patients with triple-negative breast cancer: a protocol for a systematic review. Syst Rev. 2016; 5 (1): 133. DOI: 10.1186/ s13643-016-0313-6. PubMed PMID: 27514374.
  9. Fougner C, Bergholtz H, Norum JH, Sorlie T. Re-definition of claudin-low as a breast cancer phenotype. Nat Commun. 2020; 11 (1): 1787. DOI: 10.1038/s41467-020-15574-5. PubMed PMID: 32286297.
  10. Tchou J, Wang LC, Selven B, Zhang H, Conejo-Garcia J, Borghaei H, et al. Mesothelin, a novel immunotherapy target for triple negative breast cancer. Breast Cancer Res Treat. 2012; 133 (2): 799–804. DOI: 10.1007/s10549-012-2018-4. PubMed PMID: 22418702.
  11. Lanitis E, Poussin M, Hagemann IS, Coukos G, Sandaltzopoulos R, Scholler N, et al. Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor. Mol Ther. 2012; 20(3): 633–43. DOI: 10.1038/ mt.2011.256. PubMed PMID: 22127019.
  12. Fujiwara K, Masutani M, Tachibana M, Okada N. Impact of scFv structure in chimeric antigen receptor on receptor expression efficiency and antigen recognition properties. Biochem Biophys Res Commun. 2020; 527 (2): 350–7. DOI: 10.1016/j. bbrc.2020.03.071. PubMed PMID: 32216966.
  13. Maus MV, Plotkin J, Jakka G, Stewart-Jones G, Riviere I, Merghoub T, et al. An MHC-restricted antibody-based chimeric antigen receptor requires TCR-like affinity to maintain antigen specificity. Mol Ther Oncolytics. 2016; 3: 1–9. DOI: 10.1038/ mto.2016.23. PubMed PMID: 29675462.
  14. Tillib SV. Prospective Applications of Single-Domain Antibodies in Biomedicine. Mol Biol (Mosk). 2020; 54 (3): 362–73. Epub 2020/06/04. DOI: 10.31857/S0026898420030167. PubMed PMID: 32492000.
  15. Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa EB, et al. Naturally occurring antibodies devoid of light chains. Nature. 1993; 363 (6428): 446–8. DOI: 10.1038/363446a0. PubMed PMID: 8502296.
  16. Liu W, Song H, Chen Q, Yu J, Xian M, Nian R, et al. Recent advances in the selection and identification of antigen-specific nanobodies. Mol Immunol. 2018; 96: 37–47. DOI: 10.1016/j. molimm.2018.02.012. PubMed PMID: 29477934.
  17. Prantner AM, Turini M, Kerfelec B, Joshi S, Baty D, Chames P, et al. Anti-Mesothelin Nanobodies for Both Conventional and Nanoparticle-Based Biomedical Applications. J Biomed Nanotechnol. 2015; 11 (7): 1201–12. DOI: 10.1166/ jbn.2015.2063. PubMed PMID: 26307843.
  18. Prantner AM, Yin C, Kamat K, Sharma K, Lowenthal AC, Madrid PB, et al. Molecular Imaging of Mesothelin-Expressing Ovarian Cancer with a Human and Mouse Cross-Reactive Nanobody. Mol Pharm. 2018; 15 (4): 1403–11. DOI: 10.1021/acs. molpharmaceut.7b00789. PubMed PMID: 29462558.
  19. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001; 29 (9): e45. DOI: 10.1093/nar/29.9.e45. PubMed PMID: 11328886.
  20. Fukumoto Y, Obata Y, Ishibashi K, Tamura N, Kikuchi I, Aoyama K, et al. Cost-effective gene transfection by DNA compaction at pH 4.0 using acidified, long shelf-life polyethylenimine. Cytotechnology. 2010; 62 (1): 73–82. DOI: 10.1007/s10616-010-9259-z. PubMed PMID: 20309632.
  21. Maass DR, Sepulveda J, Pernthaner A, Shoemaker CB. Alpaca (Lama pacos) as a convenient source of recombinant camelid heavy chain antibodies (VHHs). J Immunol Methods. 2007; 324 (1–2): 13–25. Epub 2007/06/15. DOI: S0022-1759(07)00119-6 [pii] 10.1016/j.jim.2007.04.008. PubMed PMID: 17568607.
  22. Benhar I, Reiter Y. Phage display of single-chain antibody constructs. Curr Protoc Immunol. 2002; 10 (10): 9B. DOI: 10.1002/0471142735.im1019bs48. PubMed PMID: 18432867.
  23. Studier FW. Protein production by auto-induction in high density shaking cultures. Protein Expr Purif. 2005; 41 (1): 207–34. PubMed PMID: 15915565.
  24. Zost SJ, Gilchuk P, Chen RE, Case JB, Reidy JX, Trivette A, et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med. 2020; 26 (9): 1422–7. DOI: 10.1038/s41591-020- 0998-x. PubMed PMID: 32651581.
  25. Liu R, Zhi X, Zhou Z, Zhang H, Yang R, Zou T, et al. Mithramycin A suppresses basal triple-negative breast cancer cell survival partially via down-regulating Kruppel-like factor 5 transcription by Sp1. Scientific reports. 2018; 8 (1): 1138. DOI: 10.1038/s41598- 018-19489-6. PubMed PMID: 29348684.
  26. Simon N, Antignani A, Sarnovsky R, Hewitt SM, FitzGerald D. Targeting a Cancer-Specific Epitope of the Epidermal Growth Factor Receptor in Triple-Negative Breast Cancer. J Natl Cancer Inst. 2016; 108 (8). DOI: 10.1093/jnci/djw028. PubMed PMID: 27075852.